Overcoming the challenge of T-cell lymphoma treatment by safe and efficacious anti-CD30 radioimmunotherapy with β-particle and ultra-short range Auger and conversion electron emitting radionuclides
Despite new therapeutic advances, aggressive T-cell lymphoma in the relapsed setting generally have unfavorable prognosis with short overall survival. Since the biology of rare T-cell lymphomas is relatively poorly understood compared to B-cell lymphomas, treatment options remain limited and unchanged for many years. Systemic radionuclide therapy uses radiopharmaceuticals that specifically target disseminated cancer cells and […]
Understanding how clonal hematopoiesis feeds lymphoma
Clonal hematopoiesis (CH) is a common premalignant condition resulting from the age-related expansion of hematopoietic stem cell clones, characterized by gene mutations or chromosomal alterations. CH can predispose individuals to various hematological and non-hematological malignancies. This study evaluated whether CH increases the risk of developing diffuse large B-cell lymphoma (DLBCL) in patients with CH mutations. […]
Effector-target cell interactions in engineered immune-therapy against hematologic malignancies
Acute myeloid leukemia (AML) is an aggressive type of blood cancer with a substantial proportion of patients not responding to available therapies. In a collaborative effort between the groups of Prof. Manz and Prof. Schroeder at USZ and ETH Zurich, scientists have developed and tested novel promising immunotherapies against AML, so called CAR-T cells and […]